PRNewsWire
03 Aug 2026, 05:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The lawsuit claims Capricor modified the statistical analysis plan for Deramiocel without securing FDA agreement prior to resubmitting a Biologics License Application. — Failure to align with the FDA on clinical analysis plans significantly increases the risk of drug rejection or regulatory delays, directly impacting the company's primary value driver.
-0.80Capricor Therapeutics (CAPR) is facing a class action lawsuit alleging it made false and misleading statements regarding clinical data for Deramiocel. — Securities litigation alleging fraud or misleading data typically triggers investor distrust and downward pressure on the stock price.
-0.60Which stocks this story touches
The company is being sued for securities law violations.
Continue reading
6 related stories
Search tags
The company is being sued for securities law violations.
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical data and FDA agreements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
54m ago
